Merck lung cancer trial boosts immunotherapy hopes – Financial Times
Financial Times |
Merck lung cancer trial boosts immunotherapy hopes
Financial Times Immunotherapy is set to become the default treatment for the vast majority of lung cancer patients after a clinical trial from drugmaker Merck & Co showed that adding its novel medicine to chemotherapy could boost survival. Unlike traditional cancer … |
